Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;81(4):426-438.
doi: 10.1111/his.14700. Epub 2022 Jun 10.

WHO 2022 landscape of papillary and chromophobe renal cell carcinoma

João Lobo  1   2   3 , Riuko Ohashi  4   5 , Mahul B Amin  6   7 , Daniel M Berney  8 , Eva M Compérat  9 , Ian A Cree  10 , Anthony J Gill  11   12   13 , Arndt Hartmann  14 , Santosh Menon  15 , George J Netto  16 , Maria R Raspollini  17 , Mark A Rubin  18   19   20 , Puay Hoon Tan  21 , Satish K Tickoo  22 , Toyonori Tsuzuki  23 , Samra Turajlic  24   25 , Ming Zhou  26 , John R Srigley  27 , Holger Moch  28
Affiliations
Review

WHO 2022 landscape of papillary and chromophobe renal cell carcinoma

João Lobo et al. Histopathology. 2022 Oct.

Abstract

The 5th edition of the WHO Classification of Tumours of the Urinary and Male Genital Systems contains relevant revisions and introduces a group of molecularly defined renal tumour subtypes. Herein we present the World Health Organization (WHO) 2022 perspectives on papillary and chromophobe renal cell carcinoma with emphasis on their evolving classification, differential diagnosis, and emerging entities. The WHO 2022 classification eliminated the type 1/2 papillary renal cell carcinoma (pRCC) subcategorization, given the recognition of frequent mixed tumour phenotypes and the existence of entities with a different molecular background within the type 2 pRCC category. Additionally, emerging entities such as biphasic squamoid alveolar RCC, biphasic hyalinising psammomatous RCC, papillary renal neoplasm with reverse polarity, and Warthin-like pRCC are included as part of the pRCC spectrum, while additional morphological and molecular data are being gathered. In addition to oncocytomas and chromophobe renal cell carcinoma (chRCC), a category of 'other oncocytic tumours' with oncocytoma/chRCC-like features has been introduced, including emerging entities, most with TSC/mTOR pathway alterations (eosinophilic vacuolated tumour and so-called 'low-grade' oncocytic tumour), deserving additional research. Eosinophilic solid and cystic RCC was accepted as a new and independent tumour entity. Finally, a highly reproducible and clinically relevant universal grading system for chRCC is still missing and is another niche of ongoing investigation. This review discusses these developments and highlights emerging morphological and molecular data relevant for the classification of renal cell carcinoma.

Keywords: chromophobe renal cell carcinoma; emerging entities; molecular pathology; papillary renal cell carcinoma; renal tumours.

PubMed Disclaimer

References

    1. Shuch B, Amin A, Armstrong AJ et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur. Urol. 2015; 67; 85-97.
    1. Cimadamore A, Cheng L, Scarpelli M et al. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. Transl. Androl. Urol. 2021; 10; 1506-1520.
    1. Raspollini MR, Moch H, Tan PH, Amin MB, Turajlic S. Renal cell tumours: Introduction. In WHO Classification of Tumours online, WHO Classification of Tumours Editorial Board eds. WHO classification of urinary and male genital tumours. 5th (beta version). Lyon: IARC Press, 2022 WHO Classification of Tumours online. [Accessed March 12, 2022]: Available from: https://tumourclassification.iarc.who.int/welcome.
    1. Escudier B, Porta C, Schmidinger M et al. Renal cell carcinoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019; 30; 706-720.
    1. Barthelemy P, Rioux-Leclercq N, Thibault C et al. Non-clear cell renal carcinomas: review of new molecular insights and recent clinical data. Cancer Treat. Rev. 2021; 97; 102191.